Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
02/2003
02/11/2003US6518421 Process for the preparation of epothilone analogs
02/11/2003US6518397 Pharmaceuticals for modulating hormone responsiveness
02/11/2003US6518316 Cytokine production and tyrosine kinase inhibitors
02/11/2003US6518303 Selectively inhibit COX-2 in preference to COX-1 and are useful in the treatment of COX-2 mediated diseases, such as inflammation, pain, fever and asthma with fewer side effects
02/11/2003US6518302 Remedies
02/11/2003US6518301 Better selectivity than estrogen for the estrogen receptor-beta over receptor-alpha; treatment of Alzheimer's disease, anxiety, depression, osteoporosis, cardiovascular disease, rheumatoid arthritis, or prostate cancer
02/11/2003US6518291 Inosine-5'-monophosphate dehydrogenase inhibitors
02/11/2003US6518281 Heterocyclic amides/imides as inhibitors of tumor necrosis factor alpha and nuclear factor kappa B and phosphodi-esterases III and IV; used to combat cachexia, endotoxic shock, retrovirus replication and asthma; antiinflammatory
02/11/2003US6518278 Administering a synergistically effective amount of irinotecane and subsequently with a synergistically effective amount of cis-oxalato (1R,2R-diaminocyclohexane) Pt (II)
02/11/2003US6518269 Cancer treatment
02/11/2003US6518268 Telomerase inhibitors and methods of their use
02/11/2003US6518267 Protease inhibitors
02/11/2003US6518264 For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders
02/11/2003US6518261 Prostate cancer
02/11/2003US6518257 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
02/11/2003US6518251 Macrolides
02/11/2003US6518248 Method of treating gastric or colon cancer by administration of a sulfoquinovosylacylglycerol ester
02/11/2003US6518247 Method for producing an antitumoral agent and antitumoral agent thus obtained
02/11/2003US6518239 Dry powder compositions having improved dispersivity
02/11/2003US6518062 Enzyme combinations for destroying proliferative cells
02/11/2003US6518061 Interleukin-13 (IL-13); Delivery of a modified Pseudomonas exotoxin (effector molecule), attached to an interleukin, to tumor cells bearing interleukin receptors; antitumor agent
02/11/2003US6518046 DNA (RNA) encoding such chemolcine polypeptides. Moreover, a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such Ck beta -9 polypeptides for the treatment of
02/11/2003US6518043 Proteins suppressing proliferation of lympho-hematopoietic cells
02/11/2003US6517889 Eliminating or minimizing coating material located within openings; contacting with coating solution then running and rotating a thread through the lumen
02/11/2003US6517841 Solid compositions and liquid preparations for oral administration which contain cocoa polyphenols
02/11/2003US6517836 Aziridin-1-yl nitrobenzamides as prodrugs in conjunction with nitroreductase enzymes
02/11/2003US6517828 C-CAM as an angiogenesis inhibitor
02/11/2003US6517810 Palliation of bone pain due to cancer by the administration of a tin stannic (Sn+4) chelate complex
02/11/2003CA2216851C Radiolabeled peptides for diagnosis and therapy
02/11/2003CA2141554C Morphogen-induced nerve regeneration and repair
02/11/2003CA2125476C 20-methyl-substituted vitamin d derivatives
02/11/2003CA2078689C Chimeric antibodies with receptor binding ligands in place of their constant region
02/10/2003WO2002014320A2 Novel substituted diaryl azepine derivatives as integrin ligands
02/10/2003CA2419078A1 Substituted diaryl azepine derivatives as integrin ligands
02/06/2003WO2003010321A1 Recombinant vectors derived from adeno-associated virus expressing tam67 for gene therapy
02/06/2003WO2003010313A1 Novel diphtheria anatoxins and their use as carrier
02/06/2003WO2003010308A2 Control of gene expression
02/06/2003WO2003010306A1 Viral mutants that selectively replicate in targeted human cancer cells
02/06/2003WO2003010301A1 New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
02/06/2003WO2003010299A1 Probiotic lactobacillus casei strains
02/06/2003WO2003010298A1 'probiotic lactobacillus salivarius strains
02/06/2003WO2003010297A1 Probiotic bifidobacterium strains
02/06/2003WO2003010290A2 Novel class ii cytokine receptors and uses thereof
02/06/2003WO2003010286A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
02/06/2003WO2003010281A2 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
02/06/2003WO2003010192A2 An inducer of apoptosis
02/06/2003WO2003010188A1 Production of high molecular mass lectins
02/06/2003WO2003010182A1 Novel dammarane sapogenins, their use as anti-cancer agents, and a process for producing same
02/06/2003WO2003010164A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/06/2003WO2003010158A1 Novel compounds
02/06/2003WO2003010139A2 Antisense modulation of hormone-sensitive lipase expression
02/06/2003WO2003010135A1 Novel phenylpropionic acid derivatives
02/06/2003WO2003009881A2 Novel targeted delivery system for bioactive agents
02/06/2003WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/06/2003WO2003009866A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent
02/06/2003WO2003009847A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003WO2003009843A1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria
02/06/2003WO2003009842A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same
02/06/2003WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
02/06/2003WO2003009833A1 Sustained release delivery system
02/06/2003WO2003009816A2 Facile detection of polycythemia vera
02/06/2003WO2003009815A2 Compositions and methods for modulating blood-brain barrier transport
02/06/2003WO2003009813A2 Methods of treating neuropilin-mediated diseases
02/06/2003WO2003009812A2 Use of glycosylceramides as adjuvants for vaccines against infections and cancer
02/06/2003WO2003009809A2 Cancer treatment with gö6976 and its related compounds
02/06/2003WO2003009805A2 Analgesic methods using endothelin receptor ligands
02/06/2003WO2003009800A1 Sustained-release therapeutic bioadhesive systems
02/06/2003WO2003009779A2 Delivery of therapeutic capable agents
02/06/2003WO2003009778A2 Methods and devices for delivery of therapeutic capable agents with variable release profile
02/06/2003WO2003009777A2 Delivery of therapeutic capable agents
02/06/2003WO2003009773A2 Removable stent and method of using the same
02/06/2003WO2002095034A3 A retinoic acid metabolizing cytochrome p450
02/06/2003WO2002093177A3 Assays for identifying modulators of rhomboid polypeptides
02/06/2003WO2002092772A3 Antisense modulation of ptp1b expression
02/06/2003WO2002092627A3 Use of casb 7439 for treatment and diagnosis of lung cancer
02/06/2003WO2002090558A9 Novel expression vectors and uses thereof
02/06/2003WO2002080940A3 Pharmacologically active strong acid solutions
02/06/2003WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
02/06/2003WO2002067851A3 Method for treating fibrotic diseases or other indications iiic
02/06/2003WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof
02/06/2003WO2002063005A3 Lipid-associated molecules
02/06/2003WO2002061110A3 Nucleic acid derivatives
02/06/2003WO2002060950A3 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
02/06/2003WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors
02/06/2003WO2002046194A3 Substituted imidazopyridines
02/06/2003WO2002041843A3 Antiinflammation agents
02/06/2003WO2002040545A9 Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
02/06/2003WO2002039995A9 Combination therapy for estrogen-dependent disorders
02/06/2003WO2002039953A3 Texaphyrin coordination compounds and uses thereof
02/06/2003WO2002032871A3 Compounds and methods for treating multidrug resistance
02/06/2003WO2002030470A9 Methods and compositions for nucleic acid delivery
02/06/2003WO2002028904A3 Human anti-cd40 antibodies
02/06/2003WO2002021996A3 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
02/06/2003WO2002020722A3 Methods and compositions for in vitro targeting
02/06/2003WO2002016965A3 Radioactive emission detector
02/06/2003WO2002016602A3 Compositions and methods for the diagnosis and treatment of tumor
02/06/2003WO2002016413A8 Cripto tumour polypeptide
02/06/2003WO2002014470A3 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth
02/06/2003WO2002010217A9 Endothelial cell expression patterns
02/06/2003WO2002010137A9 Indazole derivatives as jnk inhibitors
1 ... 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 ... 2211